Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
- Conditions
- CancerHLA-A*02:01-positive
- Interventions
- Drug: Chemotherapy drugDrug: Kinase inhibitorDrug: Antiangiogenic AgentDrug: Monoclonal antibody
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 600
- Registration Number
- NCT06840119
- Locations
- 🇪🇸
Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Australia
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 680
- Registration Number
- NCT06112314
- Locations
- 🇧🇷
Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor, Barretos, Brazil
🇧🇷Centro de Pesquisas Oncologicas (CEPON), Florianópolis, Brazil
🇧🇷Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) - Hospital Sao Lucas - Centro de Pesquisa Clinica (CPC), Porto Alegre, Brazil
Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: IMC-I109V Multiple Ascending DosesDrug: IMC-I109V Single Ascending DoseDrug: HBV HCC Module MAD
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 180
- Registration Number
- NCT05867056
- Locations
- 🇺🇸
University of Southern California Keck School of Medicine, Los Angeles, California, United States
🇺🇸University Hospitals Cleveland Medical Center Case Western Reserve, Cleveland, Ohio, United States
🇦🇺St. Vincent's Hospital, Fitzroy, Australia
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 540
- Registration Number
- NCT05549297
- Locations
- 🇺🇸
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇩🇪Charité - Campus Charité Mitte, Berlin, Germany
🇩🇪Universitaetsklinikum Erlangen, Erlangen, Germany
A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp
- Conditions
- Uveal Melanoma
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Immunocore Ltd
- Registration Number
- NCT04960891
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
- Conditions
- Select Advanced Solid Tumors
- Interventions
- Drug: Brenetafusp and chemotherapyDrug: Brenetafusp and monoclonal antibodies and chemotherapyDrug: Brenetafusp and bevacizumabDrug: Brenetafusp and kinase inhibitors
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 727
- Registration Number
- NCT04262466
- Locations
- 🇵🇱
Centrum Medyczne Pratia Poznan - Skorzewo, Skórzewo, Poland
🇵🇱Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warszawa, Poland
🇪🇸Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona, Pamplona, Navarra, Spain
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
- Conditions
- Select Advanced Solid Tumors
- Interventions
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 75
- Registration Number
- NCT03973333
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸The University of Chicago Medicine & Biological Sciences, Chicago, Illinois, United States
🇺🇸Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 29
- Registration Number
- NCT03515551
- Locations
- 🇺🇸
Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
🇺🇸University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
- Conditions
- Uveal Melanoma
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 378
- Registration Number
- NCT03070392
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
🇫🇷Centre Atoine Lacassagne, Nice, France
IMCgp100-401 Rollover Study
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 3
- Registration Number
- NCT02889861
- Locations
- 🇬🇧
Dept of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇺🇸Memorial Slone Kettering Cancer Center, New York, New York, United States
🇬🇧Dept of Oncology & Haematology, Churchill Hospital, Oxford, Oxfordshire, United Kingdom